|
GB202018950D0
|
|
Parenteral formulation
|
|
GB202018955D0
|
|
Compositions and compounds for bioanalysis
|
|
GB202013571D0
|
|
Injectable formulation
|
|
GB201917320D0
|
|
Novel compounds
|
|
GB201916210D0
|
|
High purity tryptamines and methods of synthesis thereof
|
|
GB201907871D0
|
|
Therapeutic compositions
|
|
CA3076103A1
|
|
Solid oral dosage forms of ketamine derivatives
|
|
WO2019025792A1
|
|
Crystalline forms of hydroxynorketamine
|
|
GB201808159D0
|
|
Therapeutic compositions for treating neurocognative, neurodevelopmental and psychocognitive disorders
|
|
GB201808150D0
|
|
Therapeutic compounds
|
|
WO2018104729A1
|
|
Ketamine derivatives
|
|
GB201716942D0
|
|
Therapeutic compounds
|
|
GB201715500D0
|
|
Crystal forms of therapeutic compounds and dosage forms thereof
|
|
GB201715010D0
|
|
Crystalline forms
|
|
GB201714772D0
|
|
Dosage forms of therapeutic compounds
|
|
GB201712304D0
|
|
Synthetic methods
|
|
WO2017208031A1
|
|
Solid oral dosage forms of 2r,6r-hydroxynorketamine or derivatives thereof
|
|
GB201620690D0
|
|
Ketamine derivatives
|
|
GB201609737D0
|
|
Therapeutic compounds
|
|
GB201609790D0
|
|
Therapeutic compounds
|
